File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis

TitleRisks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis
Authors
Keywordsadult
adverse outcome
ageaged
cohort analysis
drug use
Issue Date2019
PublisherWiley-Blackwell. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2036
Citation
Alimentary Pharmacology and Therapeutics, 2019, v. 50 n. 9, p. 1001-1008 How to Cite?
AbstractBackground: Selective serotonin reuptake inhibitors (SSRIs) are the first‐line treatment for depression but there is a concern about the risk of upper gastrointestinal bleeding (UGIB). Past studies, however, are largely confounded by the presence of Helicobacter pylori (HP). Aim: To evaluate the UGIB risk of SSRI users after treatment for HP. Methods: This was a propensity score (PS) matched cohort study with patients who used SSRI after receiving HP eradication therapy from the Hong Kong territory‐wide healthcare database. The primary outcome was hospitalisation for nonvariceal UGIB. PS matching analysis with a ratio of 1:2 plus Cox regression model was used to compute the hazards ratios (HR) and 95% CI of UGIB risk. Results: In this study, 3358 SSRI users and 57 906 non‐users were included. The median follow‐up duration was 7.74 (interquartile range 5.32‐10.42) years. The crude incidence of hospitalisation for UGIB was 3.98 (95% CI 3.80‐4.16) per 1000 person‐years. In the PS matching analysis of 3358 SSRI users with 6716 non‐users, SSRI was associated with a higher risk of UGIB compared to non‐users (HR 1.95, 95% CI 1.41‐2.70). This result was consistent in sensitivity analysis with 1:1 PS matching (HR 2.13, 95% CI 1.50‐3.02) and multivariable analysis with 1‐month intervals (HR 1.81, 95% CI 1.34‐2.45) or 3‐month intervals (HR 1.61, 95% CI 1.20‐2.17). After stratifying by age, the increased risk of SSRI was only significant among patients >50 years. Conclusion: SSRI users have a higher risk of hospitalisation for nonvariceal UGIB after treatment for HP, particularly among older patients.
Persistent Identifierhttp://hdl.handle.net/10722/278594
ISSN
2023 Impact Factor: 6.6
2023 SCImago Journal Rankings: 2.794
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGuo, CG-
dc.contributor.authorCheung, KS-
dc.contributor.authorZhang, F-
dc.contributor.authorChan, EW-
dc.contributor.authorChen, L-
dc.contributor.authorWong, ICK-
dc.contributor.authorLeung, WK-
dc.date.accessioned2019-10-21T02:10:25Z-
dc.date.available2019-10-21T02:10:25Z-
dc.date.issued2019-
dc.identifier.citationAlimentary Pharmacology and Therapeutics, 2019, v. 50 n. 9, p. 1001-1008-
dc.identifier.issn0269-2813-
dc.identifier.urihttp://hdl.handle.net/10722/278594-
dc.description.abstractBackground: Selective serotonin reuptake inhibitors (SSRIs) are the first‐line treatment for depression but there is a concern about the risk of upper gastrointestinal bleeding (UGIB). Past studies, however, are largely confounded by the presence of Helicobacter pylori (HP). Aim: To evaluate the UGIB risk of SSRI users after treatment for HP. Methods: This was a propensity score (PS) matched cohort study with patients who used SSRI after receiving HP eradication therapy from the Hong Kong territory‐wide healthcare database. The primary outcome was hospitalisation for nonvariceal UGIB. PS matching analysis with a ratio of 1:2 plus Cox regression model was used to compute the hazards ratios (HR) and 95% CI of UGIB risk. Results: In this study, 3358 SSRI users and 57 906 non‐users were included. The median follow‐up duration was 7.74 (interquartile range 5.32‐10.42) years. The crude incidence of hospitalisation for UGIB was 3.98 (95% CI 3.80‐4.16) per 1000 person‐years. In the PS matching analysis of 3358 SSRI users with 6716 non‐users, SSRI was associated with a higher risk of UGIB compared to non‐users (HR 1.95, 95% CI 1.41‐2.70). This result was consistent in sensitivity analysis with 1:1 PS matching (HR 2.13, 95% CI 1.50‐3.02) and multivariable analysis with 1‐month intervals (HR 1.81, 95% CI 1.34‐2.45) or 3‐month intervals (HR 1.61, 95% CI 1.20‐2.17). After stratifying by age, the increased risk of SSRI was only significant among patients >50 years. Conclusion: SSRI users have a higher risk of hospitalisation for nonvariceal UGIB after treatment for HP, particularly among older patients.-
dc.languageeng-
dc.publisherWiley-Blackwell. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2036-
dc.relation.ispartofAlimentary Pharmacology and Therapeutics-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectadult-
dc.subjectadverse outcome-
dc.subjectageaged-
dc.subjectcohort analysis-
dc.subjectdrug use-
dc.titleRisks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis-
dc.typeArticle-
dc.identifier.emailCheung, KS: cks634@hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityCheung, KS=rp02532-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityLeung, WK=rp01479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/apt.15507-
dc.identifier.pmid31583734-
dc.identifier.scopuseid_2-s2.0-85073477948-
dc.identifier.hkuros308236-
dc.identifier.hkuros306048-
dc.identifier.volume50-
dc.identifier.issue9-
dc.identifier.spage1001-
dc.identifier.epage1008-
dc.identifier.isiWOS:000488747200001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0269-2813-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats